Menorrhagia — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Menorrhagia, also recognized as heavy menstrual bleeding, significantly hampers regular activities, impacts quality of life, and induces anemia in approximately two-thirds of women experiencing objective Menorrhagia (defined as a loss of 80 mL blood per cycle). Termed abnormal uterine bleeding for precision, Menorrhagia can be categorized into nine groups under the PALM-COEIN acronym:
1. Polyp
2. Adenomyosis
3. Leiomyoma
4. Malignancy and hyperplasia
5. Coagulopathy
6. Ovulatory dysfunction stemming from conditions like hypothyroidism, hyperthyroidism, prolactin-secreting tumors, or PCOS
7. Endometrial factors
8. Iatrogenic causes, such as the use of IUDs, chemotherapeutic agents, or anticoagulants
9. Unclassified origins
The pathophysiology of abnormal uterine bleeding (AUB) mirrors the diversity encapsulated by its classification. AUB can arise from pelvic anomalies like distortion of the endometrial cavity due to fibroids, endometrial protrusions into the cervix or vagina (polyps), or friable endometrial tissue. Additionally, certain medications can lead to AUB, including but not limited to:
· Warfarin, aspirin, clopidogrel, and other anticoagulants
· Contraceptive medications and devices
· Tamoxifen
· Tricyclic antidepressants
· Antipsychotics
· Corticosteroids
The primary treatments for Menorrhagia associated with ovulatory cycles, considered first-line options, are nonhormonal in nature: namely, the antifibrinolytic tranexamic acid and nonsteroidal anti-inflammatory drugs.
Thelansis’s “Menorrhagia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menorrhagia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Menorrhagia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Menorrhagia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Menorrhagia, Menorrhagia market outlook, Menorrhagia competitive landscape, Menorrhagia market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
